A research network in formation
Bringing rigorous research practice to a new class of immune therapy.
The MDRing Clinical Partner Network is assembling rheumatology, orthopedic, sports medicine and regenerative practices to serve as sites and investigators for FDA-supervised clinical studies of an investigational cord-blood-derived regulatory T-cell therapy, developed by Cellenkos, in inflammatory joint and autoimmune conditions.
Cellenkos has taken cord-blood-derived regulatory T cells through FDA-supervised studies in several serious diseases. Whether these cells have any role in inflammatory joint and autoimmune conditions is an open question — and answering it properly is what this network exists to do.
Start where it matters to you
Three areas, each covered in full. Most physicians evaluating a research role want the science before anything else; most practice leaders start with what participation actually involves.
The Opportunity
What a research role involves, the two kinds of partner we are looking for, the regional pairing model, the markets we are building in, and what participating sites receive.
Read moreThe Science
Regulatory T cells explained plainly, how the product is made, the studies Cellenkos has run in other conditions — and a direct account of what is not yet known.
Read moreOur Approach to Compliance
Why this network intends to work only through the FDA's investigational pathway, what IND and IRB mean in practice, and the responsibilities that come with being an investigator.
Read more
The network at a glance
- Target metro areas
- 22Active and under consideration, from California to New Jersey.
- Site selection criteria
- 7Clinical and research grounds only.
- Conditions with FDA-supervised studies
- 5All serious or life-threatening. None are joint conditions.
- Clinical results in joint conditions
- 0None exist yet. That is what the network's studies are designed to answer.
What this network is, and what it is not
What it is
- A network of physician practices being recruited to act as clinical study sites and investigators.
- A research programme intended to run under FDA oversight, with independent ethics review at every site.
- An effort to generate the clinical evidence that does not yet exist for these cells in joint and autoimmune conditions.
What it is not
- A treatment programme. The therapy is investigational and has not been approved by the FDA for any joint, arthritis, pain or wound condition.
- A patient-facing service. No study in these conditions is open, and this site does not accept patient enquiries.
- A claim that these cells work. No clinical data exists in these conditions yet. That is precisely the gap the network's studies are designed to address.
Who we are talking to
The network is being built around practices that already see the relevant patients and can meet the standards of a regulated study.
- 1.
Rheumatology practices
Physicians treating rheumatoid arthritis, psoriatic arthritis and related immune-mediated conditions, often with established clinical trial experience and research infrastructure already in place.
- 2.
Orthopedic and sports medicine practices
Practices managing inflamed and degenerative joints in active adults, with the clinical volume and follow-up discipline a study protocol requires.
- 3.
Regenerative medicine practices
Practices experienced with procedural therapies and structured consent, who understand the difference between an office-based procedure and a laboratory-manufactured investigational cell product.
- 4.
Multi-site groups and networks
Larger organisations able to contribute several sites, coordinated research operations, and established investigator and data infrastructure.
If your practice would take this seriously, we would like to talk.
We are selecting a small number of sites per market. The first conversation is about fit: your patient population, your research capacity, and what a study in these conditions would need from you.
Become a Study Site